Jeff Jones
Stock Analyst at Oppenheimer
(0.58)
# 3,761
Out of 4,827 analysts
87
Total ratings
15.79%
Success rate
-23.14%
Average return
Main Sectors:
Stocks Rated by Jeff Jones
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRVS Corvus Pharmaceuticals | Reiterates: Outperform | $15 → $17 | $4.32 | +293.52% | 5 | May 9, 2025 | |
| IMCR Immunocore Holdings | Maintains: Outperform | $85 → $86 | $28.80 | +198.61% | 2 | May 8, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Outperform | $60 → $56 | $6.42 | +772.27% | 9 | May 7, 2025 | |
| ZURA Zura Bio | Maintains: Outperform | $20 → $19 | $1.22 | +1,457.38% | 3 | Mar 26, 2025 | |
| ALMS Alumis | Initiates: Outperform | $32 | $5.15 | +521.36% | 1 | Jan 30, 2025 | |
| EVH Evolent Health | Maintains: Outperform | $28 → $18 | $9.50 | +89.57% | 4 | Jan 24, 2025 | |
| CLRB Cellectar Biosciences | Downgrades: Perform | n/a | $0.25 | - | 5 | Dec 11, 2024 | |
| CATX Perspective Therapeutics | Maintains: Outperform | $22 → $16 | $2.36 | +577.97% | 7 | Nov 22, 2024 | |
| YMAB Y-mAbs Therapeutics | Initiates: Outperform | $23 | $3.97 | +479.35% | 1 | Nov 18, 2024 | |
| CMMB Chemomab Therapeutics | Reiterates: Outperform | $13 → $11 | $1.27 | +766.14% | 7 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 → $9 | $1.31 | +587.02% | 10 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $56 | $30.40 | +84.21% | 4 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $35 → $39 | $20.35 | +91.65% | 2 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $45 | $1.43 | +3,046.85% | 6 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $6.97 | - | 4 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.17 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 | $0.26 | +45,596.88% | 3 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $6.69 | - | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $0.90 | +1,566.67% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $75 | $1.04 | +7,111.54% | 2 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,600 → $1,100 | $1.50 | +73,233.33% | 2 | Nov 17, 2022 |
Corvus Pharmaceuticals
May 9, 2025
Reiterates: Outperform
Price Target: $15 → $17
Current: $4.32
Upside: +293.52%
Immunocore Holdings
May 8, 2025
Maintains: Outperform
Price Target: $85 → $86
Current: $28.80
Upside: +198.61%
Corbus Pharmaceuticals Holdings
May 7, 2025
Maintains: Outperform
Price Target: $60 → $56
Current: $6.42
Upside: +772.27%
Zura Bio
Mar 26, 2025
Maintains: Outperform
Price Target: $20 → $19
Current: $1.22
Upside: +1,457.38%
Alumis
Jan 30, 2025
Initiates: Outperform
Price Target: $32
Current: $5.15
Upside: +521.36%
Evolent Health
Jan 24, 2025
Maintains: Outperform
Price Target: $28 → $18
Current: $9.50
Upside: +89.57%
Cellectar Biosciences
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $0.25
Upside: -
Perspective Therapeutics
Nov 22, 2024
Maintains: Outperform
Price Target: $22 → $16
Current: $2.36
Upside: +577.97%
Y-mAbs Therapeutics
Nov 18, 2024
Initiates: Outperform
Price Target: $23
Current: $3.97
Upside: +479.35%
Chemomab Therapeutics
Nov 15, 2024
Reiterates: Outperform
Price Target: $13 → $11
Current: $1.27
Upside: +766.14%
Nov 8, 2024
Reiterates: Outperform
Price Target: $10 → $9
Current: $1.31
Upside: +587.02%
Sep 27, 2024
Maintains: Outperform
Price Target: $52 → $56
Current: $30.40
Upside: +84.21%
Sep 10, 2024
Reiterates: Outperform
Price Target: $35 → $39
Current: $20.35
Upside: +91.65%
Aug 8, 2024
Maintains: Outperform
Price Target: $48 → $45
Current: $1.43
Upside: +3,046.85%
Jun 7, 2024
Downgrades: Perform
Price Target: n/a
Current: $6.97
Upside: -
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.17
Upside: -
May 25, 2023
Maintains: Outperform
Price Target: $120
Current: $0.26
Upside: +45,596.88%
May 23, 2023
Downgrades: Perform
Price Target: n/a
Current: $6.69
Upside: -
May 11, 2023
Reiterates: Outperform
Price Target: $15
Current: $0.90
Upside: +1,566.67%
Mar 24, 2023
Reiterates: Outperform
Price Target: $75
Current: $1.04
Upside: +7,111.54%
Nov 17, 2022
Maintains: Outperform
Price Target: $1,600 → $1,100
Current: $1.50
Upside: +73,233.33%